However, our findings are consistent with those of studies of multiple myeloma, in which concurrent inhibition of MEK and CHK1 caused synergistic growth suppression in vitro and in vivo (Dai et al., 2008; Pei et al., 2011). The gene discussed is MAP2K7; the disease is plasma cell myeloma.